Dr. Antin-Ozerkis received her Bachelor’s degree from Princeton University. She went on to complete her medical degree, residency, and fellowship in Pulmonary and Critical Care Medicine at the University of Pennsylvania, where she pursued advanced fellowship training in the evaluation and management of advanced lung disease and lung transplant patients. She came to Yale in 2006. Dr. Antin-Ozerkis is Medical Director of the Yale Interstitial Lung Disease Center of Excellence.
There are many forms of interstitial lung disease (ILD), which is sometimes called pulmonary fibrosis. When a patient comes the Yale ILD Center of Excellence, we perform a thorough evaluation which focuses on determining which form of ILD the patient has. This allows the medical team to establish an individualized treatment plan. Our program stresses a "whole patient approach" which means that in addition to medication, we also focus on exercise, nutrition, oxygen (when necessary), and quality of life.
Specific forms of ILD that we see include: idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD (including lung disease related to rheumatoid arthritis, scleroderma/ systemic sclerosis, dermatomyositis and polymyositis, Sjogren's syndrome, and lupus), as well as sarcoidosis, hypersensitivity pneumonitis and other forms of occupational lung disease.
We have a multidisciplinary program with specialists in pulmonology, radiology, pathology, occupational medicine and rheumatology. Cases are discussed in our group weekly with a goal of finding the correct diagnosis and determining the most appropriate treatment plan. We offer clinical trial enrollment for interested patients and have several open trials for patients with idiopathic pulmonary fibrosis and scleroderma lung disease.
- Connective Tissue Diseases
- Lung Diseases
- Pulmonary Fibrosis
- Lung Diseases, Interstitial
Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians
Patient Care Organizations
Internal Medicine AB of Internal Medicine (2002)
|Diseases of the Lung, Diseases of the Respiratory System, Diseases of the Respiratory Systems||A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis|